Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 10, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its...
Hankook & Company Group Completes Acquisition of Hanon Systems
"Tires, Batteries, Thermal Management": Completing Three Core Portfolios to Become a Global High-Tech Leading Group 10 Years of Investment Culminates in Stable Integration, Synergy Creation, and Financial Structure Improvement Soo Il Lee Appointed...